W
351.60
6.22 (1.80%)
| Previous Close | 345.38 |
| Open | 343.49 |
| Volume | 533,250 |
| Avg. Volume (3M) | 553,438 |
| Market Cap | 20,923,400,192 |
| Price / Earnings (TTM) | 31.93 |
| Price / Earnings (Forward) | 22.42 |
| Price / Sales | 5.71 |
| Price / Book | 8.04 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 22.02% |
| Operating Margin (TTM) | 22.93% |
| Diluted EPS (TTM) | 11.01 |
| Quarterly Revenue Growth (YOY) | 3.90% |
| Quarterly Earnings Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 78.58% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | 758.81 M |
| Levered Free Cash Flow (TTM) | 588.83 M |
| Return on Assets (TTM) | 11.61% |
| Return on Equity (TTM) | 40.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Waters Corporation | Bearish | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -4.0 |
| Average | -0.88 |
|
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 98.23% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 385.00 (Jefferies, 9.50%) | Buy |
| Median | 352.00 (0.11%) | |
| Low | 315.00 (Deutsche Bank, -10.41%) | Hold |
| 315.00 (Wells Fargo, -10.41%) | Hold | |
| Average | 348.40 (-0.91%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 298.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 05 Aug 2025 | 315.00 (-10.41%) | Hold | 281.19 |
| Wells Fargo | 05 Aug 2025 | 315.00 (-10.41%) | Hold | 281.19 |
| 15 Jul 2025 | 330.00 (-6.14%) | Hold | 289.56 | |
| Jefferies | 04 Aug 2025 | 385.00 (9.50%) | Buy | 285.59 |
| Baird | 16 Jul 2025 | 352.00 (0.11%) | Buy | 289.56 |
| B of A Securities | 26 Jun 2025 | 375.00 (6.66%) | Hold | 354.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Aug 2025 | Announcement | Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results |
| 14 Jul 2025 | Announcement | Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing |
| 11 Jul 2025 | Announcement | Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call |
| 17 Jun 2025 | Announcement | Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity |
| 02 Jun 2025 | Announcement | Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer |
| 28 May 2025 | Announcement | Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality |
| 21 May 2025 | Announcement | Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |